{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:42:01Z","timestamp":1772890921393,"version":"3.50.1"},"reference-count":78,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Cardiovascular Disease"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p> Cardiovascular (CV) disease is a major cause of morbidity and mortality in the developing and the developed world. Mortality from CV disease had plateaued in the recent years raising concerning alarms about the sustained efficacy of available preventive and treatment options. Heart failure (HF) is among the major contributors to the CV-related health care burden, a persisting concern despite the use of clinically proven guideline-directed therapies. A requirement for more efficient medical therapies coupled with recent advances in bio-innovation led to the creation of sacubitril\/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), which demonstrated substantial CV benefit when compared with the standard of care, enalapril, in patients with HF and reduced ejection fraction. Further investigations of this novel combination ARNI at the tissue level shed light into the anti-remodeling and cardioprotective effects of sacubitril\/valsartan, while clinical studies in the phenotypes of HF with preserved ejection fraction, hypertension and subsets, coronary outcomes, postmyocardial infarction, and renal disease suggested that this combination could be beneficial across a wide spectrum of CV disease. Sacubitril\/valsartan is a much-needed therapeutic advance in the avenue of CV disease. <\/jats:p>","DOI":"10.1177\/1753944718784536","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T05:02:19Z","timestamp":1529470939000},"page":"217-231","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Sacubitril\/valsartan in cardiovascular disease: evidence to date and place in therapy"],"prefix":"10.1177","volume":"12","author":[{"given":"Srikanth","family":"Yandrapalli","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New York Medical College at Westchester Medical Center, Valhalla, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Hasan","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogita","family":"Rochlani","sequence":"additional","affiliation":[{"name":"Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7945-9863","authenticated-orcid":false,"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Professor of Medicine, Cardiology Division, New York Medical College at Westchester Medical Center, Macy Pavilion, Room 141, Valhalla, NY 10595, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"key":"bibr1-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.052"},{"key":"bibr2-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000350"},{"key":"bibr3-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61889-4"},{"key":"bibr4-1753944718784536","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2017.68813"},{"key":"bibr5-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"bibr6-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000473"},{"key":"bibr7-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007273430403"},{"key":"bibr8-1753944718784536","first-page":"1531","volume":"287","author":"Publication Committee for the VMAC Investigators","year":"2002","journal-title":"JAMA"},{"key":"bibr9-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100171"},{"key":"bibr10-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.108.767483"},{"key":"bibr11-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.282190"},{"key":"bibr12-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.01.022"},{"key":"bibr13-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl337"},{"key":"bibr14-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601895"},{"key":"bibr15-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2011.08082.x"},{"key":"bibr16-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)77712-6"},{"key":"bibr17-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199207000-00002"},{"key":"bibr18-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.26.6.1160"},{"key":"bibr19-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.23.2323"},{"key":"bibr20-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.1998.1201"},{"key":"bibr21-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1042\/bj2410237"},{"key":"bibr22-1753944718784536","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2002.023"},{"key":"bibr23-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000029801.86489.50"},{"key":"bibr24-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2003.09.014"},{"key":"bibr25-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009343932"},{"key":"bibr26-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2210-11-S1-P33"},{"key":"bibr27-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61227-6"},{"key":"bibr28-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.76"},{"key":"bibr29-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001427"},{"key":"bibr30-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.232"},{"key":"bibr31-1753944718784536","unstructured":"Novartis. Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF), http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01920711. NLM identifier: NCT01920711 (accessed 20 December 2017)."},{"key":"bibr32-1753944718784536","unstructured":"Novartis. A randomized, double-blind controlled study comparing LCZ696 to medical therapy for comorbidities in HFpEF Patients (PARALLAX), http:\/\/clinicaltrials.gov\/ct2\/show\/NCT03066804. NLM identifier: NCT03066804 (accessed 20 December 2017)."},{"key":"bibr33-1753944718784536","unstructured":"Novartis. Study of efficacy and safety of LCZ696 in Japanese patients with chronic heart failure and reduced ejection fraction (PARALLEL-HF), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02468232. NLM identifier: NCT02468232 (accessed 20 December 2017)."},{"key":"bibr34-1753944718784536","unstructured":"Novartis. ARNI in Asymptomatic patients with elevated natriuretic peptide and elevated left atrial volume index elevation (PARABLE), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02682719. NLM identifier: NCT02682719 (accessed 29 December 2017)."},{"key":"bibr35-1753944718784536","unstructured":"Novartis. Comparison of pre- and post-discharge Initiation of LCZ696 Therapy in HFrEF patients after an acute decompensation event (TRANSITION), http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02661217. NLM identifier: NCT02661217 (accessed 29 December 2017)."},{"key":"bibr36-1753944718784536","unstructured":"Novartis. Comparison of sacubitril\/valsartan enalapril on effect on ntpRo-bnp in patients stabilized from an acute heart failure episode (PIONEER-HF), http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02554890. NLM identifier: NCT02554890 (accessed 28 December 2017)."},{"key":"bibr37-1753944718784536","unstructured":"Novartis. Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after MI (PARADISE-MI), http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02924727. NLM identifier: NCT02924727 (accessed 29 December 2017)."},{"key":"bibr38-1753944718784536","unstructured":"Novartis. Patient registry assessing effectiveness and safety of heart failure treatment with LCZ696 across Canada (PARTHENON), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02957409. NLM identifier: NCT02957409 (accessed 29 December 2017)."},{"key":"bibr39-1753944718784536","unstructured":"Novartis. Effects of sacubitril\/valsartan therapy on biomarkers, myocardial remodeling and outcomes. (PROVE-HF), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02887183. NLM identifier: NCT02887183 (accessed 29 December 2017)."},{"key":"bibr40-1753944718784536","unstructured":"Novartis. Efficacy and safety of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejection fraction (PERSPECTIVE), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02884206. NLM identifier: NCT02884206 (accessed 29 December 2017)."},{"key":"bibr41-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61966-8"},{"key":"bibr42-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02002"},{"key":"bibr43-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv186"},{"key":"bibr44-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560"},{"key":"bibr45-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2015.06.158"},{"key":"bibr46-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.08.878"},{"key":"bibr47-1753944718784536","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ejhf.258","volume":"17","author":"B\u00f6hm M","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"bibr48-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv330"},{"key":"bibr49-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013748"},{"key":"bibr50-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu455"},{"key":"bibr51-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw226"},{"key":"bibr52-1753944718784536","volume-title":"Paper presented at American College of Cardiology Scientific Sessions","author":"Simpson J"},{"key":"bibr53-1753944718784536","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S114784"},{"key":"bibr54-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000571"},{"key":"bibr55-1753944718784536","unstructured":"Novartis. EntrestoTM (LCZ696) in advanced heart failure (LIFE study) (HFN-LIFE), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02816736. NLM identifier: NCT02816736 (accessed 29 December 2017)."},{"key":"bibr56-1753944718784536","unstructured":"Novartis. Study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of LCZ696 followed by a 52-week study of LCZ696 compared with enalapril in pediatric patients with heart failure, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02678312. NLM identifier: NCT02678312 (accessed 29 December 2017)."},{"key":"bibr57-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.02.034"},{"key":"bibr58-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785"},{"key":"bibr59-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.474"},{"key":"bibr60-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-017-0013-4"},{"key":"bibr61-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2017.08.001"},{"key":"bibr62-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12667"},{"key":"bibr63-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001219"},{"key":"bibr64-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08556"},{"key":"bibr65-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08484"},{"key":"bibr66-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.455"},{"key":"bibr67-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2015.1"},{"key":"bibr68-1753944718784536","first-page":"2043","volume":"32","author":"Haynes R","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"bibr69-1753944718784536","unstructured":"Haynes R, Judge P, Staplin N, et al. Randomized multicentre pilot study of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (UK HARP)-III. Poster presented at American Society of Nephrology Scientific Sessions; November 2017; Washington, DC, http:\/\/www.harp3trial.org\/ASN%20HARP3%20LBCT.pdf (accessed 29 December 2017)."},{"key":"bibr70-1753944718784536","unstructured":"Novartis. Pulmonary artery pressure reduction with Entresto (sacubitril\/valsartan) (PARENT), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02788656. NLM identifier: NCT02788656 (accessed 29 December 2017)."},{"key":"bibr71-1753944718784536","unstructured":"Novartis. Pharmacological reduction of functional, ischemic mitral regurgitation (PRIME), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02687932. NLM identifier: NCT02687932 (accessed 30 December 2017)."},{"key":"bibr72-1753944718784536","unstructured":"Novartis. Comparing ARNI with ACE inhibitor on endothelial function (PARADOR), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03119623. NLM identifier: NCT03119623 (accessed 30 December 2017)."},{"key":"bibr73-1753944718784536","unstructured":"Novartis. Use of Entresto sacubitril\/valsartan for the treatment of peripheral arterial disease, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02636283. NLM identifier: NCT02636283 (accessed 30 December 2017)."},{"key":"bibr74-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.02.004."},{"key":"bibr75-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018622"},{"key":"bibr76-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509"},{"key":"bibr77-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.08.022"},{"key":"bibr78-1753944718784536","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"}],"container-title":["Therapeutic Advances in Cardiovascular Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753944718784536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1753944718784536","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753944718784536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T15:12:28Z","timestamp":1740755548000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753944718784536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1177\/1753944718784536"],"URL":"https:\/\/doi.org\/10.1177\/1753944718784536","relation":{},"ISSN":["1753-9447","1753-9455"],"issn-type":[{"value":"1753-9447","type":"print"},{"value":"1753-9455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]}}}